

# Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Benefit Assessment under Section 35a SGB V on Melatonin (new therapeutic indication: insomnia in neurogenetic diseases;  $\geq 2$  to  $\leq 18$  years)

of 17 October 2024

The Federal Joint Committee (G-BA) decided the following at its session on 17 October 2024:  
The benefit assessment procedure on melatonin according to Section 35a paragraph 1 SGB V for a new therapeutic indication (treatment of insomnia in children and adolescents aged 2-18 years with [...] neurogenetic disorders with aberrant diurnal melatonin secretion and/or night-time awakenings, where sleep hygiene measures have been insufficient.), which was initiated on 1 October 2024, is suspended.

The justification to this resolution will be published on the website of the G-BA at [www.g-ba.de](http://www.g-ba.de).

Berlin, 17 October 2024

Federal Joint Committee (G-BA)  
in accordance with Section 91 SGB V  
The Chair

Prof. Hecken